The relationship between variations in antipsychotic prescribing across nursing homes and short-term mortality: Quality of care implications

Medical Care

Volumn 47, Issue 9, 2009, Pages 1000-1008

  Bronskill, Susan E ^a,b   Rochon, Paula A ^a,b,c   Gill, Sudeep S ^a,d   Herrmann, Nathan ^b,e   Hillmer, Michael P ^f   Bell, Chaim M ^a,b,g   Anderson, Geoffrey M ^a,b   Stukel, Thérèse A ^a,b  

^a INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c WOMEN S COLLEGE HOSPITAL   (Canada)

^d QUEEN S UNIVERSITY   (Canada)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f ONTARIO MINISTRY OF HEALTH AND LONG TERM CARE   (Canada)

^g ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Antipsychotic drugs; Cohort study; Nursing home; Quality of care; Variation

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CHOLINESTERASE INHIBITOR; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PERICIAZINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TRIFLUOPERAZINE;

AGED; ARTICLE; CANADA; CONTROLLED STUDY; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NURSING HOME; OUTCOME ASSESSMENT; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MALE; MORTALITY; NURSING HOMES; ONTARIO; PHYSICIAN'S PRACTICE PATTERNS; PROPORTIONAL HAZARDS MODELS; QUALITY OF HEALTH CARE;

EID: 69449097739     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e3181a3943f     Document Type: Article

References (40)

1. Ray WA, Federspiel CF, Schaffner W. A study of antipsychotic drug use in nursing homes: epidemiologic evidence suggesting misuse. Am J Public Health. 1980;70:485-491. (Pubitemid 10098089)
2. Hughes CM, Lapane KL. Administrative initiatives for reducing inappropriate prescribing of psychotropic drugs in nursing homes: how successful have they been? Drugs Aging. 2005;22:339-351.
3. Briesacher BA, Limcangco MR, Simoni-Wastila L, et al. The quality of antipsychotic drug prescribing in nursing homes. Arch Intern Med. 2005;165:1280-1285. (Pubitemid 40989593)
4. Oborne CA, Hooper R, Li KC, et al. An indicator of appropriate neuroleptic prescribing in nursing homes. Age Ageing. 2002;31:435-439. (Pubitemid 35452787)
5. Omnibus Budget Reconciliation Act of 1987 (OBRA 87), P.L. 100-203, Subtitle C: Nursing Home Reform. Washington, DC: US Government Printing Office; 1987.
6. Center for Health Systems Research and Analysis. Wisconsin Medicaid Nursing Home Drug Quality Indicator Report User Guide, December 2004. Available at: http://www.chsra.wisc.edu/chsra/qi/guide-drug.pdf. Accessed September 1, 2008.
7. Hughes CM, Lapane K, Watson MC, et al. Does organizational culture influence prescribing in care homes for older people? A new direction for research. Drugs Aging. 2007;24:81-93. (Pubitemid 46327568)
8. Briesacher B, Limcangco R, Simoni-Wastila L, et al. Evaluation of nationally mandated drug use reviews to improve patient safety in nursing homes: a natural experiment. J Am Geriatr Soc. 2005;53:991-996. (Pubitemid 41647596)
9. Fahey T, Montgomery AA, Barnes J, et al. Quality of care for elderly residents in nursing homes and elderly people living at home: controlled observational study. BMJ. 2003;326:580. (Pubitemid 36337586)
10. Bronskill SE, Anderson GM, Sykora K, et al. Neuroleptic drug therapy in older adults newly admitted to nursing homes: incidence, dose, and specialist contact. J Am Geriatr Soc. 2004;52:749-755. (Pubitemid 38596494)
11. Rochon PA, Stukel TA, Bronskill SE, et al. Variation in nursing home antipsychotic prescribing rates. Arch Intern Med. 2007;167:676-683.
12. Rochon PA, Normand SL, Gomes T, et al. Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med. 2008;168:1090-1096. (Pubitemid 351749226)
13. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006;355:1525-1538. (Pubitemid 44547805)
14. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934-1943. (Pubitemid 41464695)
15. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353:2335-2341. (Pubitemid 41713745)
16. Schneeweiss S, Setoguchi S, Brookhart A, et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176:627-632. (Pubitemid 46426056)
17. Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146:775-786. (Pubitemid 351650498)
18. US Food and Drug Administration. FDA Issues Public Health Advisory for Antipsychotic Drugs Used for Treatment of Behavioral Disorders in Elderly Patients. Talk Paper T05-13. April 2005. Available at: http://www.fda.gov/bbs/ topics/ANSWERS/2005/ANS01350.html. Accessed June 26, 2008.
19. Health Canada. Health Canada Advises Consumers about Important Safety Information on Atypical Antipsychotic Drugs and Dementia. Advisory 2005-2063. June 2005. Available at: http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/ 2005/2005-63-e.html. Accessed June 26, 2008.
20. US Food and Drug Administration. FDA Alert: Information for Healthcare Professionals - Antipsychotics. June 16, 2008. Available at: http://www.fda.gov/cder/drug/InfoSheets/HCP/antipsychotics-conventional.htm. Accessed June 26, 2008.
21. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360:225-235.
22. Stukel TA, Fisher ES, Wennberg DE, et al. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA. 2007;297:278-285.
23. Schneeweiss S, Seeger JD, Maclure M, et al. Performance of comorbid- ity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001;154:854-864. (Pubitemid 33000813)
24. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
25. Stukel TA, Lucas FL, Wennberg DE. Long-term outcomes of regional variations in intensity of invasive vs medical management of Medicare Patients with acute myocardial infarction. JAMA. 2005;293:1329-1337.
26. Liperoti R, Mor V, Lapane KL, et al. The use of atypical antipsychotics in nursing homes. J Clin Psychiatry. 2003;64:1106-1112. (Pubitemid 37158258)
27. Spiegelhalter DJ. Funnel plots for comparing institutional performance. Stat Med. 2005;24:1185-1202.
28. Cox DR, Oakes D. Analysis of Survival Data. New York, NY: Chapman Hall; 1984.
29. Lin DY. Cox regression analysis of multivariate failure time data: the marginal approach. Stat Med. 1994;13:2233-2247.
30. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med. 1997;157:1531-1536.
31. Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163:2716-2724.
32. Wagner AK, Zhang F, Soumerai SB, et al. Benzodiazepine use and hip fractures in the elderly: who is at greatest risk? Arch Intern Med. 2004;164:1567-1572. (Pubitemid 38970480)
33. Herrmann N, Gill SS, Bell CM, et al. A population-based study of cholinesterase inhibitor use for dementia. J Am Geriatr Soc. 2007;55:1517-1523. (Pubitemid 47508507)
34. Anderson GM, Beers MH, Kerluke K. Auditing prescription practice using explicit criteria and computerized drug benefit claims data. J Eval Clin Pract. 1997;3:283-294. (Pubitemid 127498574)
35. Gruneir A, Lapane KL. It is time to assess the role of organizational culture in nursing home prescribing patterns. Arch Intern Med. 2008;168:238-239. (Pubitemid 351185898)
36. Newhouse JP, McClellan M. Econometrics in outcomes research: the use of instrumental variables. Annu Rev Public Health. 1998;19:17-34. (Pubitemid 28279922)
37. Hughes CM, Lapane KL, Mor V. Influence of facility characteristics on use of antipsychotic medications in nursing homes. Med Care. 2000;38:1164-1173.
38. Hillmer MP, Wodchis WP, Gill SS, et al. Nursing home profit status and quality of care: is there any evidence of an association? Med Care Res Rev. 2005;62:139-166.
39. Avorn J, Soumerai SB, Everitt DE, et al. A randomized trial of a program to reduce the use of psychoactive drugs in nursing homes. N Engl J Med. 1992;327:168-173.
40. Fossey J, Ballard C, Juszczak E, et al. Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. BMJ. 2006;332:756-761. (Pubitemid 44365651)